Medical/Pharmaceuticals Global News & Press Release Distribution

Medical/Pharmaceuticals

All
APAC

Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS

NANTONG and SUZHOU, China, Nov. 19, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RAG-21, its novel siR...

2024-11-19 21:26 1164

Health2Sync Partners with Singapore Health Promotion Board and Abbott to Launch Innovative DigiCoach Program Tackling Pre-diabetes and Obesity

* "DigiCoach program" is a pilot program by Singapore Health Promotion Board, Health2Sync, and Abbott that aims to help individuals with pre-diabetes or high BMI prevent or delay the onset of diabetes. * Participants can use a continuous glucose monitoring (CGM) device and the Health2Sync mob...

2024-11-19 21:00 1256

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

Highlights: * Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) * Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by ~...

2024-11-19 20:30 1273

RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development

BEIJING, Nov. 19, 2024 /PRNewswire/ -- With the support of the RiDYMO® platform, we are able to comprehensively explore various potential targets in drug development, including protein-protein interactions, kinases, GPCRs, ion channels, and transcription factors. Polo-like kinase 1 (PLK1) is a h...

2024-11-19 16:00 1035

RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development

TAHO Pharmaceuticals Initiates U.S. Phase III Clinical Trial of TAH3311 Antithrombotic Oral Dissolving Film, Dosing First Subjects

TAIPEI, Nov. 19, 2024 /PRNewswire/ -- TAHO Pharmaceuticals Ltd. announced the dosing of the first subjects in its U.S. Phase III clinical trial for its lead product, TAH3311, an innovative antithrombotic oral dissolving film (ODF). In July 2023, the U.S. Food & Drug Administration (FDA) accepted T...

2024-11-19 14:08 1217

SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player

* SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using analpha-particle emitting radioisotope, actinium-225, for potential cancer treatments * The two sides aim to submit an Investigatio...

2024-11-19 08:00 1672

Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at American College of Rheumatology (ACR) Convergence 2024

* 78-Week results from Phase III randomized controlled trial (RCT) including switching data from reference denosumab to CT-P41 (biosimilar candidate of denosumab) demonstrate comparable efficacy and safety results; Results support the therapeutic equivalence of CT-P41 and reference denosumab in...

2024-11-19 02:15 1391

WAT Medical Continues Support for Red Cross and Veterans Association

VANCOUVER, BC, Nov. 18, 2024 /PRNewswire/ -- WAT Medical Enterprise Ltd. proudly reaffirms its commitment to community support by donating to the American Red Cross and the American Veterans Association. These donations are part of the company's pledge to contribute a portion of the proceeds from...

2024-11-18 22:30 979

WAT Medical Continues Support for Red Cross and Veterans Association

C Ray Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital

CHENGDU, China, Nov. 18, 2024 /PRNewswire/ -- In November 2024, C Ray Therapeutics (Chengdu) Co., Ltd. (hereinafter referred to as "C Ray"), an innovative enterprise in the field of radiopharmaceuticals, announced the completion of its Series A+ financing round exceeding$100 million. This round ...

2024-11-18 22:00 1754

C Ray Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital

Lunit Announces Collaboration with AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for NSCLC

Collaboration to harness Lunit SCOPE Genotype Predictor for rapid and convenient prediction of non-small cell lung cancer driver mutations SEOUL, South Korea, Nov. 18, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, ...

2024-11-18 22:00 1557

Lunit Announces Collaboration with AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for NSCLC

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

* Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics; additional regulatory and sales milestone payments exceed$900M with tiered single digit sal...

2024-11-18 21:50 1335

Akeso Biopharma to Attend Jefferies London Healthcare Conference and Morgan Stanley 23rd Asia Pacific Summit

HONG KONG, Nov. 18, 2024 /PRNewswire/ -- Akeso Biopharma (9926. HK) ("Akeso" or the "Company") is pleased to announce thatDr. Michelle Xia, the company's founder, chairwoman, president, and CEO, will attend Morgan Stanley's 23rd Asia Pacific Summit.Dr. Bing C. Wang, the company's chief financial ...

2024-11-18 21:16 1232

WELLlife COVID-19/Influenza A&B Home Test on Sale for Black Friday and Cyber Monday

BOLINGBROOK, Ill. , Nov. 18, 2024 /PRNewswire/ -- Stock up your family's medicine cabinet this Black Friday and Cyber Monday. WELLlife, a leading innovator in medical diagnostic and testing solutions, is increasing accessibility to respiratory illness testing in preparation for the year-end holi...

2024-11-18 21:00 1033

WELLlife COVID-19/Influenza A&B Home Test on Sale for Black Friday and Cyber Monday

TenNor Announces Positive Topline Results from Rifasutenizol Phase III Trial for H. pylori Infection

SUZHOU, China, Nov 18, 2024 /PRNewswire/ -- TenNor Therapeutics, a clinical-stage company dedicated to developing novel therapies to address unmet needs in infectious diseases, announced today the successful completion of a phase III clinical trial of rifasutenizol (TNP-2198) for the treatment of...

2024-11-18 19:00 1199

FDA Grants Breakthrough Therapy Designation to Huahui Health's Libevitug (HH-003) for treatment of chronic Hepatitis D virus infection

BEIJING, Nov. 18, 2024 /PRNewswire/ -- Huahui Health, a clinical-stage biotechnology company focused on discovering and developing novel therapies in the areas of viral hepatitis, hepatology, and oncology, today announced that its investigational hepatitis D and B drug candidate, Libevitug (HH-00...

2024-11-18 18:40 1067

SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors

TEL AVIV, Israel, Nov. 14, 2024 /PRNewswire/ -- SoniVie Ltd. , a medical device company developing a proprietary renal denervation system to treat hypertension, announced today the appointment ofRaymond W. Cohen to serve as its chairman of the board of directors. Mr. Coh...

2024-11-18 08:00 1239

Neurophet Appoints CTO Donghyeon Kim as Co-CEO, Joining Jake Junkil Been in Dual Leadership to Drive Global Growth

- Donghyeon Kim, Co-Founder and CTO of Neurophet, to Take On Dual Role as CEO, Heading Technology and Company Leadership - Aims to Strategically Expand Business and Management Functions for Establishing a Strong Presence in Global Markets SEOUL, South Korea, Nov. 15, 2024 /PRNewswire/ -- Neuroph...

2024-11-15 22:00 1661

Neurophet Appoints CTO Donghyeon Kim as Co-CEO, Joining Jake Junkil Been in Dual Leadership to Drive Global Growth

Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in IgG4-Related Disease

* IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program * ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing cells currently being investigated in non-Hodgkin's lymphoma (NHL) * The planned clinical ...

2024-11-15 20:00 1314

Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 14, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...

2024-11-15 09:55 1315

Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Approved for 2 Clinical Trials by CDE of NMPA

SHANGHAI, Nov. 14, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its novel Nectin-4 targeting ADC (R&D code: 9MW2821) has received IND approval for two clinical studies. The first will explore its use in combination wi...

2024-11-14 22:00 1646

1 ... 5 6 789 10 11 ... 219